The R&D Value Cycle of Nano-Enabled Medical Devices – The Case of Biosensors

Nano-enabled devices leverage two general phenomena that occur at the nano-scale: (a) transitions in physiochemical properties, and (b) transitions in biochemical interactions. Evidently, the R&D value cycle is very scientist-driven, revolving around university departments generating new opportu...

Full description

Bibliographic Details
Main Author: C.G. Siontorou
Format: Article
Language:English
Published: AIDIC Servizi S.r.l. 2014-08-01
Series:Chemical Engineering Transactions
Online Access:https://www.cetjournal.it/index.php/cet/article/view/5375
id doaj-5c40ceb38e234b468fd368ac2d953eea
record_format Article
spelling doaj-5c40ceb38e234b468fd368ac2d953eea2021-02-21T20:59:17ZengAIDIC Servizi S.r.l.Chemical Engineering Transactions2283-92162014-08-013910.3303/CET1439074The R&D Value Cycle of Nano-Enabled Medical Devices – The Case of BiosensorsC.G. SiontorouNano-enabled devices leverage two general phenomena that occur at the nano-scale: (a) transitions in physiochemical properties, and (b) transitions in biochemical interactions. Evidently, the R&D value cycle is very scientist-driven, revolving around university departments generating new opportunities for transfer of instrumentation and techniques across disciplinary boundaries in order to formulate a proof-of-concept into a successful interaction with the industry that will attain its market integration. This paper uses biosensors as an exemplar to study the dynamic structure of this innovation system, in an attempt to frame it by considering (i) its scientific basis, towards (but not through) its commercial applications (within- academy R&D), and (ii) the factors intrinsic to the technology itself (technology barriers) that could ultimately determine its rate of commercialization (R&D transfer from academy to industry). The results indicate that different research strategies decided upon at the academy level can enhance or thwart industry’s ability to appropriate the value of the university output, whereas market-oriented technology trajectories and roadmaps drawn at the industry level can increase uncertainty and risk if the diffusive and elusive nature of academic research is neglected.https://www.cetjournal.it/index.php/cet/article/view/5375
collection DOAJ
language English
format Article
sources DOAJ
author C.G. Siontorou
spellingShingle C.G. Siontorou
The R&D Value Cycle of Nano-Enabled Medical Devices – The Case of Biosensors
Chemical Engineering Transactions
author_facet C.G. Siontorou
author_sort C.G. Siontorou
title The R&D Value Cycle of Nano-Enabled Medical Devices – The Case of Biosensors
title_short The R&D Value Cycle of Nano-Enabled Medical Devices – The Case of Biosensors
title_full The R&D Value Cycle of Nano-Enabled Medical Devices – The Case of Biosensors
title_fullStr The R&D Value Cycle of Nano-Enabled Medical Devices – The Case of Biosensors
title_full_unstemmed The R&D Value Cycle of Nano-Enabled Medical Devices – The Case of Biosensors
title_sort r&d value cycle of nano-enabled medical devices – the case of biosensors
publisher AIDIC Servizi S.r.l.
series Chemical Engineering Transactions
issn 2283-9216
publishDate 2014-08-01
description Nano-enabled devices leverage two general phenomena that occur at the nano-scale: (a) transitions in physiochemical properties, and (b) transitions in biochemical interactions. Evidently, the R&D value cycle is very scientist-driven, revolving around university departments generating new opportunities for transfer of instrumentation and techniques across disciplinary boundaries in order to formulate a proof-of-concept into a successful interaction with the industry that will attain its market integration. This paper uses biosensors as an exemplar to study the dynamic structure of this innovation system, in an attempt to frame it by considering (i) its scientific basis, towards (but not through) its commercial applications (within- academy R&D), and (ii) the factors intrinsic to the technology itself (technology barriers) that could ultimately determine its rate of commercialization (R&D transfer from academy to industry). The results indicate that different research strategies decided upon at the academy level can enhance or thwart industry’s ability to appropriate the value of the university output, whereas market-oriented technology trajectories and roadmaps drawn at the industry level can increase uncertainty and risk if the diffusive and elusive nature of academic research is neglected.
url https://www.cetjournal.it/index.php/cet/article/view/5375
work_keys_str_mv AT cgsiontorou therdvaluecycleofnanoenabledmedicaldevicesthecaseofbiosensors
AT cgsiontorou rdvaluecycleofnanoenabledmedicaldevicesthecaseofbiosensors
_version_ 1724257566911889408